Eun Yang
Recent Quotes
"OPK's interim Phase 2 data for Lagova in pediatric growth hormone deficiency (GHD) is encouraging."
—
Eun Yang, Jefferies & Co.
(6/24/14)
more >
"OPK's 4Kscore is positioned to reduce the number of unnecessary prostate biopsies."
—
Eun Yang, Jefferies & Co.
(6/3/14)
more >
"OPK's Q1/14E cash of ~$156M should be sufficient into 2015."
—
Eun Yang, Jefferies & Co.
(5/13/14)
more >
"OPK's YE/13 cash of ~$186M should be sufficient thru H1/16."
—
Eun Yang, Jefferies & Co.
(3/4/14)
more >
"Preclinical pharmacokinetic data for OPK's FVIIa-CTP are encouraging."
—
Eun Yang, Jefferies & Co.
(2/28/14)
more >
"PSTI has enough cash for ~2 years."
—
Eun Yang, Jefferies & Co.
(11/21/13)
more >
"OPK will be in the top 25 market cap companies on the TASE."
—
Eun Yang, Jefferies & Co.
(9/9/13)
more >
"OPK's cash of ~$169M should be sufficient into 2015."
—
Eun Yang, Jefferies & Co.
(8/12/13)
more >
